90% of Tesla's story is about AI and autonomous driving, says Wedbush's Dan Ives
Dan Ives, Wedbush Securities, joins 'Closing Bell Overtime' to talk Tesla and Microsoft earnings. Petrified wood is one of ...
The DeepSeek panic sell-off is a golden buying opportunity for Nvidia, says Wedbush's Dan Ives
Wedbush’s Dan Ives and Laffer’s Nancy Tengler, join 'Power Lunch' to discuss the DeepSeek sell-off and how to play the tech ...
What is DeepSeek, and why is it causing Nvidia and other stocks to slump?
Chinese startup DeepSeek has debuted an AI app that challenges OpenAI's ChatGPT and other U.S. rivals, sending a shock ...
Intel price target lowered to $20 from $25 at Wedbush
Wedbush analyst Matt Bryson lowered the firm’s price target on Intel (INTC) to $20 from $25 and keeps a Neutral rating on the ...
DeepSeek Dip a "Buying Opportunity" for Nvidia and U.S. Tech Stocks, Says Wedbush
The market reacted negatively to DeepSeek's open-source AI release through shares of Nvidia ( NVDA, Financial) and U.S. tech ...
FY2024 EPS Estimates for STAG Industrial Boosted by Wedbush
Equities researchers at Wedbush raised their FY2024 earnings per share (EPS) estimates for STAG Industrial in a report issued ...
General Motors' Turnaround On Track Despite EV Roadblocks – Analysts Say
GM reports strong Q4 earnings despite EV hurdles; analysts remain optimistic about long-term growth and turnaround potential.
MarketWatch1mon
AI revolution will create 10 winners in 2025 — and software is finally joining the party
Technology stocks are expected to gain 25% in 2025 once the new administration ushers in a less stringent regulatory regime, according to Wedbush, where analysts are expecting the AI revolution to ...
Palantir price target raised to $90 from $75 at Wedbush
Wedbush raised the firm’s price target on Palantir (PLTR) to $90 from $75 and keeps an Outperform rating on the shares. The firm says growing ...
Oklo price target raised to $45 from $26 at Wedbush
Wedbush analyst Daniel Ives raised the firm’s price target on Oklo (OKLO) to $45 from $26 and keeps an Outperform rating on the shares as the ...
FY2024 Earnings Forecast for RARE Issued By Wedbush
Wedbush upped their FY2024 EPS estimates for Ultragenyx Pharmaceutical in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will ...